In short
Clinical trials of AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING THE HUMAN BETA-GLOBIN GENE are studying gene therapy in people with transfusion-dependent beta-thalassemia. The main goal is to check safety and whether treatment can help patients become free from regular blood transfusions. The trial includes pediatric and adult patients.
Key points
- Clinical trials of AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING THE HUMAN BETA-GLOBIN GENE are studying transfusion-dependent beta-thalassemia. The available trial is a Phase 2, single-arm, open-label, multicenter study with 9 participants. It includes pediatric and adult patients. The main goal is to see whether patients can achieve transfusion independence for at least 12 months. The key outcome also checks whether hemoglobin stays at a weighted average of at least 9.0 g/dL during that time.
Trial overview
The available study is a single-arm trial, which means everyone in the study receives the same study treatment and there is no separate comparison group in the trial data provided. It is also open label, so both the study team and the participants know what treatment is being given. The study is multicenter, meaning it takes place at more than one site.
This Phase 2b clinical study is evaluating gene therapy using AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING THE HUMAN BETA-GLOBIN GENE in people with transfusion-dependent beta-thalassemia. The study is authorised and planned as a single-dose trial.
Who the trial is for
The trial includes pediatric and adult patients with transfusion-dependent beta-thalassemia. This means the study is looking at both children and adults who need regular blood transfusions because of their condition.
The source data do not list more detailed eligibility rules, such as age limits, lab values, or prior treatment requirements.
How the study is designed
This is an interventional study, which means the researchers are giving a treatment and then measuring the results. The trial is in Phase 2, a stage that usually focuses on early signs of benefit while continuing to monitor safety.
The trial uses a single-dose approach and has an enrollment of 9 participants. The study title also says it uses an improved transduction protocol, which means the way the cells are prepared and modified has been updated, but the source data do not give technical details.
What the study measures
The main outcome is the proportion of subjects achieving transfusion independence. In this study, transfusion independence is defined as a weighted average hemoglobin level of at least 9.0 g/dL without any red blood cell transfusion for a continuous period of at least 12 months.
The study says the 12-month transfusion independence assessment starts 60 days after the last red blood cell transfusion used for post-transplant support or standard care for beta-thalassemia. This is important because it shows how the trial counts the time without transfusions.
Treatments used in the trial
The intervention list includes AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING THE HUMAN BETA-GLOBIN GENE given by intravenous administration. The trial also lists Busulfan, GRANOCYTE, and Plerixafor as study drugs used in the treatment process.
The source data do not explain the exact role of each of these additional drugs, so the article only notes that they are part of the study intervention list.
Key patient points
- The trial is focused on transfusion-dependent beta-thalassemia, a condition that often requires regular blood transfusions.
- It is a Phase 2 study with 9 participants, so it is a small early-stage trial.
- The main question is whether patients can become transfusion independent for at least 12 months.
- The study includes both children and adults, but the source data do not give more detailed entry rules.
- The trial is authorised and open label, so the treatment plan is known to the study team and participants.